Kainos Medicine, Inc. (KOSDAQ:284620)
South Korea flag South Korea · Delayed Price · Currency is KRW
1,087.00
-105.00 (-8.81%)
At close: Aug 14, 2025

Kainos Medicine Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-6,332-7,785-12,190-15,235-15,881-16,212
Depreciation & Amortization
277.99591.341,1521,2771,262809.72
Loss (Gain) From Sale of Assets
18.2221.46--650.8332.01-48.87
Asset Writedown & Restructuring Costs
1,2051,205363---
Loss (Gain) From Sale of Investments
5.734.53719.3265.12535.81-125.76
Loss (Gain) on Equity Investments
1,6692,044410.11---
Stock-Based Compensation
120.0837.56643.721,0261,9362,932
Other Operating Activities
-1,634-1,169-1,354-301.47-525.355,226
Change in Accounts Receivable
121.25-5.42-152.2213.64--
Change in Inventory
--681.82----
Change in Income Taxes
0.0239.867.16-85.34-23.8614.51
Change in Other Net Operating Assets
1,259-218.91632.54-330.411,368-1,791
Operating Cash Flow
-3,766-5,917-9,709-14,221-11,296-9,195
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-2.12-5.52-0.08-3,998-1,826-1,939
Sale of Property, Plant & Equipment
---8,3511.8212.95
Sale (Purchase) of Intangibles
-284.99-266.11-206.94-100-639.29-456.41
Investment in Securities
---3,5404,8205,366-3,657
Other Investing Activities
251.5679.3217.25-17.61-118.1685.66
Investing Cash Flow
-35.55-442.31-4,0799,0552,785-5,753

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
---4,9001,246-
Long-Term Debt Issued
----761.671,523
Total Debt Issued
---4,9002,0081,523
Short-Term Debt Repaid
----5,662--
Long-Term Debt Repaid
--369.63-587.23-2,944-20,918-362.66
Total Debt Repaid
-326.85-369.63-587.23-8,605-20,918-362.66
Net Debt Issued (Repaid)
-326.85-369.63-587.23-3,705-18,9101,161
Issuance of Common Stock
-5,7341,643-28,28413,308
Repurchase of Common Stock
-2.26----32.4-
Other Financing Activities
-0-0-0--197.79
Financing Cash Flow
-329.115,3641,056-3,7059,34214,667

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
99.2526.84229.18256.76890.71,561
Miscellaneous Cash Flow Adjustments
0-----
Net Cash Flow
-4,032-967.83-12,503-8,6151,7211,279

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-3,769-5,922-9,709-18,220-13,122-11,134
Free Cash Flow Growth
------
Free Cash Flow Margin
-268.29%-505.48%-1644.59%-6815.87%-10092.16%-669.76%
Free Cash Flow Per Share
-114.74-187.20-348.85-652.51-550.49-525.41
Levered Free Cash Flow
-2,493-4,888-5,744-11,695-16,9271,540
Unlevered Free Cash Flow
-2,483-4,870-5,714-11,547-16,0832,588

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
0.30.43-157.59--
Cash Income Tax Paid
-2.281.091.041.030.92
Change in Working Capital
902.91-866.36547.48-402.11,344-1,776